Patients with CHF and depression have greater risk of mortality and morbidity than patients without depression: Reply  by Vaccarino, Viola
tality no longer existed. The adverse effects of moderate depression
on functional decline were also diminished (see their Table 3 [1]).
These results raise two concerns. First, as the investigators noted
in their study, GDS is a valid measure for depressive symptoms
among the elderly, but it is not equivalent to a clinical diagnosis of
depression through standard diagnostic interviewing. Second, how
many variables to include as adjustment factors (given the number
of events) and the identification of potentially confounding factors
remain as challenges.
We studied 374 hospitalized patients similar to those in the
Vaccarino et al. (1) study, except our cohort included subjects ages
18 and up, between March 1997 and June 1998 (4). We used the
Beck Depression Inventory (BDI) to screen for the presence of
depressive symptoms. Patients with a BDI score 10 underwent
standardized psychiatric diagnostic interviewing for the clinical
diagnosis of major depressive disorder according to DSM-IV criteria.
Patients were followed at 3 months and 12 months for repeat
hospitalization and mortality. We found that the mortality rate in HF
patients with major depression was about 2.5 times higher than in HF
patients without depression (BDI score 10) at 12 months, and a
similar trend was noted at 3 months. The incidence of repeat
hospitalization also followed a similar pattern. The adverse association
between depression and HF prognosis was not diminished after
adjustment for variables commonly considered to be confounding
factors in this population—age, New York Heart Association func-
tional class, baseline ejection fraction, and etiology of HF—suggesting
that major depression independently affects prognosis in HF.
We observed that the predictive ability of the BDI score (10
vs. 10) was more powerful at 3 months than at 12 months, when
it diminished somewhat. In contrast, the prognostic ability of
major depression appeared stronger over time. Given our under-
standing of HF, and the limited existing knowledge of its inter-
action with psychiatric disorders, we therefore consider a standard-
ized diagnostic interview to be necessary in addition to self-
administered instruments.
We are pleased our findings have been reproduced to a certain
degree at different tertiary-care settings. Despite the limitations of
both studies, there should be little doubt about the adverse effects
of depression on the short-term prognosis of recent inpatients with
HF. Whether such an adverse effect carries over to the long term
and whether treatment of depression can improve these poorer
outcomes demand study. The prognostic association between
depression and clinically stable HF also must be examined.
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We thank Dr. Jiang and colleagues for their thoughtful comments.
We were pleased to read their well-done study (1) published
almost concurrently with ours (2). Whereas their study shares a
number of similarities with ours, it also presents a number of
differences that might explain why the association of depression
with mortality was stronger in their study than in ours. First, as
these investigators point out, the assessment of depression was
different in the two studies.
Second, the populations of heart failure (HF) patients also
differed. In the attempt to restrict HF to cases of ischemic or
hypertensive etiology, we included predominantly elderly patients
(50 years and older), and the mean age of our sample was 73 years.
In contrast, Jiang and colleagues enrolled patients 18 years and
older. As a result, their population was much younger and most
likely it included a broader variety of HF etiology.
Third, while we assessed mortality at six months, Jiang et al.
assessed this outcome at three months and one year. The associ-
ation of depression with death may vary according to length of
follow-up. These investigators, for example, observed that major
depression was more strongly associated with mortality at one year
than at three months. At three months, this association was not
significant in their study, and the point estimate was not very
different from our estimate for “severe depression” at six months.
Therefore, it might be that if a longer follow-up were available in
our study, we would have observed a stronger association as well.
Fourth, while Jiang and colleagues adjusted for a number of
potential confounders, they did not include in their models a
number of covariables that were adjusted for in our study,
including race, education, previous hospitalizations for HF, dia-
betes, systolic blood pressure, serum creatinine and patient’s
self-reported disability level (number of limitations in activities of
daily living). Our study, therefore, might have obtained a tighter
control for potential confounders, especially those factors related to
disease severity and comorbidity. We do not believe that model
overfitting was a problem in our analysis, because the relative risk
estimate declined toward the null with progressive adjustment for
potential confounders, and because a reduced model provided
similar results.
However, in our study, depression was still associated with
substantial (although nonsignificant) mortality risk. Patients with
severe depression had 68% higher mortality risk compared with
nondepressed patients, and there was a dose-response relationship
with mortality according to severity of depressive symptoms. As we
pointed out in our study, our main focus was the examination of
the association of depression with functional decline. Our study
was not powered to examine mortality as a separate end point, and
a larger study might have found such a mortality difference to be
statistically significant. We concur with Dr. Jiang and colleagues
that, based on the results of both studies, depression poses serious
adverse effects on the outcomes of patients with HF.
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